The RHIC sponsors small exploratory pilot projects with potential for a high level of innovation. The projects are eligible for funding at a level of $25,000 to $35,00 a year for a one-year period. Renewal for an additional year will be based on pilot project progress. Investigators will be asked to discuss their project progress at Rochester Human Immunology Center meetings once or twice per year. Suitable pilot projects will be small, exploratory projects with a high level of innovation. Projects that take advantage of existing clinical trials to analyze the immunological mechanisms underlying drug or vaccine efficacy or disease mechanism; and projects with the potential to advance utilization of developing technology for immune status assessments in man are encouraged. Although human immunology projects are preferred, projects involving animal models highly relevant to human disease will be considered. A brief proposal (maximum two pages) including introduction, project summary, and specific aims must be submitted electronically for review. Four to six investigators will be invited to present their proposals at Human Immunology seminars prior to the final selection of pilot projects by the RHIC Executive Committee and the RHIC External Advisory Board.
New funding cycles will be announced yearly through the Rochester Human Immunology Center mailing list and through posted announcements through the URMC and River Campus. If you would like to receive automatic updates about the RHIC, it is suggested that you join the mailing list. Pleast contact Sally Quataert to join. If you have any questions, please contact either Dr. Sally Quataert, 273-2454 or Dr. Tim Mosmann, 275-9120.
The Rochester Human Immunology Center (RHIC) grant has been renewed, and we will be continuing the Pilot Project program that supported several successful grant applications in the last funding cycle. We announce a new Request for Proposals for two Pilot Projects to be funded in May 2009. The application deadline is March 16, 2009. The pilot projects are eligible for funding at a level of $25,000 to $35,00 a year for a one-year period. Renewal for an additional year will be considered, based on pilot project progress.
Suitable pilot projects will be small, exploratory projects with a high level of innovation. We encourage submission of projects that take advantage of existing clinical trials to analyze the immunological mechanisms underlying drug or vaccine efficacy or disease mechanism; and projects with the potential to advance utilization of developing technology for immune status assessments in man. Projects with a high potential for development into full-scale R21 or R01 projects will be given preference. Although human immunology projects are preferred, projects involving animal models highly relevant to human disease will be accepted. The expertise of the RHIC Core Lab is available to support Pilot Projects, particularly for investigators with interesting ideas from outside the field of immunology.
Proposals (maximum two pages excluding references) should include an introduction placing the project in context, a project summary, specific aims, and preliminary data if available. Also attach an NIH- format biosketch, and a brief budget (e.g. 10-20 lines). Please send proposals electronically to: Sally_Quataert@urmc.rochester.edu. If you have any questions, please contact either Dr. Sally Quataert, 273-2454 or Dr. Tim Mosmann, 275-9120.
Four to six applicants will be invited to present their proposals at Human Immunology seminars during April 2009 prior to the final selection of pilot projects for funding by the HIC External Advisors and Executive Committee. Investigators will be asked to discuss their project progress at Human Immunology Center meetings once or twice per year.
Director and Michael and Angela Pichichero Director’s Endowed Chair
Director, Human Immunology Center Core Laboratory
David H. Smith Center for Vaccine Biology and Immunology
Aab Institute of Biomedical Sciences
University of Rochester Medical Center
601 Elmwood Avenue, Box 609
Rochester, New York 14642-8609
Previously Funded Pilot Projects and Outcomes
“Discriminating between cell populations by optical spectroscopy and multivariate statistics” by Andrew Berger: Pilot funding and RHIC expertise supported analysis of cells using Raman spectroscopy and elastic scattering. A R21 proposal, "IRAM: Integrated Raman and Angular-scatter Microscopy" based on the pilot program data was funded.
“Application of label-free sensor systems in immunology: Use of Arrayed Imaging Reflectometry for the detection and quantitation of cytokines in human plasma.” by Ben Miller: This pilot project led to three publications for surface plasma refraction detection of biological markers, and is proposed as a directed development project because of its potential for low cost, high sensitivity, multiplexed optical sensor biomarker detection. This work also led to two awards to Pathologics, LLC (PI Chris Striemer, with Ben Miller as PI on URMC subcontracts): HHSN261200700042C, "Label-free Antibody Arrays for Cancer Diagnostics", 1R43ES016406-01, “A Rapid Label-Free Sensor for Immune Markers of Environmental Exposure”
“Near-infrared reflectance confocal imaging of immune cells in-vivo” by Jim Zavislan: The project demonstrated feasibility in vivo near-infrared reflectance confocal imaging in human skin of T and B cell activation responses in delayed-type hypersensitivity, and the results are being applied in clinical studies.
“Transfection of cell arrays using femtosecond lasers” by Wayne Knox: Transfection was attempted in human and monkey cells by targeting the cells with tightly-focused 27 fs laser pulses. The microscope is currently being re-designed to provide more control over the location and movement of the laser beam.
“Overcoming the possible immunosupression from human regulatory T-cells and negative co-stimulatory molecules in non-Hodgkin’s lymphoma (NHL); A strategy to augment the efficacy of immunotherapy”, by Steve Bernstein and Shannon Hilchey. Magnetic bead removal of unusually potent T regulatory (CD4+CD25+) cells from lymphoma lymph node cell populations allowed proliferation of tumor infiltrating CD4+ CD25- lymph node cells. This data formed the basis of funded RO1 grant.
“The Role of human IL-2+IFNg-IL-4- CD4+ T helper cells in helping B cell antibody secretion.” by Anagha Divekar and Tim Mosmann: We have identified cognate and bystander help for B cell proliferation and antibody secretion by tetanus- and influenza-specific human Th1, Th2 and Thpp cells. This Pilot provided preliminary data for the successful NYICE contract.